Monday Jun 23, 2025
NEWSLETTER
www.israelhayom.com
  • Home
  • Iran War
  • News
    • Gaza War
    • US Election Coverage
    • Middle East
    • Cyber & Internet
    • Business & Finance
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
  • Home
  • Iran War
  • News
    • Gaza War
    • US Election Coverage
    • Middle East
    • Cyber & Internet
    • Business & Finance
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
Home Special Coverage Coronavirus Outbreak

Report: New corona vaccine appears safe, effective in early trials

Phase I trials of adenovirus vaccine from China's CanSino Biologics Inc. "represent an important milestone," Professor Wei Shen of the Beijing Institute of Biotechnology says.

by  News Agencies and ILH Staff
Published on  05-24-2020 12:00
Last modified: 11-16-2021 15:43
Coronavirus vaccine could be 18 months away, experts sayGetty Images

Vaccine to treat the coronavirus could take at least a year and a half until it reaches the general public | Illustration: Getty Images

Share on FacebookShare on Twitter

A coronavirus vaccine developed by CanSino Biologics Inc appears to be safe and induced a rapid immune response in its first human trial, Chinese researchers reported on Friday in The Lancet medical journal.

CanSino uses a weakened common cold virus called an adenovirus -- and Friday's study showed people whose bodies recognized that cold virus didn't get as much of the presumed COVID-19 benefit. To avoid that problem, the Oxford vaccine uses an adenovirus that normally infects chimpanzees.

Follow Israel Hayom on Facebook and Twitter

This vaccine did not cause any serious adverse effects, the researchers say, though they did report some side effects such as fever. Furthermore, blood samples from the 108 vaccinated adults showed so-called neutralizing antibodies and T-cell responses against the novel coronavirus, a sign of possible efficacy.

"These results represent an important milestone," coauthor Professor Wei Chen from the Beijing Institute of Biotechnology said in a statement.

"The ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. We are still a long way from this vaccine being available to all," the researcher added. Further studies will be needed to confirm whether the vaccine protects against infection. The first such trial is underway in Wuhan, China.

All 108 test participants were quarantined in a hotel for 14 days after vaccination, to ensure they weren't exposed to the coronavirus during a study meant to track safety.

CanSino is awaiting results from 500 volunteers injected in a next-step study. In Britain's soon-to-begin larger tests, researchers will address how Oxford's shot will affect older adults, who are at high risk from COVID-19. Pollard noted that people over 70 often don't get as much protection from vaccines as younger people.

Related Posts

A bat from the past? Scientists identify new Covid-like virusThomas Peter/Reuters

A bat from the past? Scientists identify new Covid-like virus

by Adi Nirman

Discovery at Wuhan facility shows virus uses similar cell entry mechanism as COVID-19.

Israel reinstates PCR tests at Ben-Gurion AirportYossi Zeliger

Israel reinstates PCR tests at Ben-Gurion Airport

by Shimon Yaish

Travelers returning from abroad can be tested for COVID at the government's expense. Testing is voluntary, for now.

Israel launches COVID vaccination campaign for children 5 and youngerGetty Images

Israel launches COVID vaccination campaign for children 5 and younger

by Maytal Yasur Beit-Or

Parents inoculating young children will be able to choose between Moderna and Pfizer shots. Healthcare providers stress the importance of...

Menu

Analysis 

Archaeology

Blogpost

Business & Finance

Culture

Exclusive

Explainer

Environment

 

Features

Health

In Brief

Jewish World

Judea and Samaria

Lifestyle

Cyber & Internet

Sports

 

Diplomacy 

Iran & The Gulf

Gaza Strip

Politics

Shopping

Terms of use

Privacy Policy

Submissions

Contact Us

About Us

The first issue of Israel Hayom appeared on July 30, 2007. Israel Hayom was founded on the belief that the Israeli public deserves better, more balanced and more accurate journalism. Journalism that speaks, not shouts. Journalism of a different kind. And free of charge.

All rights reserved to Israel Hayom

Hosted by sPD.co.il

  • Home
  • Iran War
  • News
    • Gaza War
    • US Election Coverage
    • Middle East
    • Cyber & Internet
    • Business & Finance
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il

Newsletter

[contact-form-7 id=”508379″ html_id=”isrh_form_Newsletter_en” title=”newsletter_subscribe”]

  • Home
  • Iran War
  • News
    • Gaza War
    • US Election Coverage
    • Middle East
    • Cyber & Internet
    • Business & Finance
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il